Opus Genetics (IRD) Amortization of Deferred Charges (2010 - 2017)
Opus Genetics (IRD) posted quarterly Amortization of Deferred Charges of $219577.0 for Q4 2017, down 34.07% quarter-over-quarter from $333050.0 in Q2 2017.
Powered by 
Analysis
Opus Genetics (IRD) Amortization of Deferred Charges (2010 - 2017) Analysis & Trends
Opus Genetics (IRD) has reported Amortization of Deferred Charges for 6 consecutive years, with $219577.0 the latest figure, recorded in Q4 2017.
- In Q4 2017, Amortization of Deferred Charges changed N/A year-over-year to $219577.0; the TTM figure through Dec 2017 stood at $552627.0 (up 76.51% YoY), while the FY2017 annual figure was $552627.0, up 76.51% from the prior year.
- Amortization of Deferred Charges eased to $219577.0 in Q4 2017 per IRD's latest filing, from $333050.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $333050.0 in Q2 2017 and bottomed at $91653.0 in Q4 2013.
- Historically, Amortization of Deferred Charges has averaged $182300.1 across 4 years, with a median of $169887.0 in 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2017 | 219,577.00 |
| Jun 30, 2017 | 333,050.00 |
| Sep 30, 2016 | 143,203.00 |
| Mar 31, 2016 | 169,887.00 |
| Mar 31, 2014 | 206,172.00 |
| Dec 31, 2013 | 91,653.00 |
| Sep 30, 2013 | 112,559.00 |
| Mar 31, 2011 | 97,667.00 |
| Jun 30, 2010 | 180,080.00 |